Dr James Garner is an experienced life sciences executive, whose career has focused on the development and commercialization of novel therapeutics for diseases with high unmet medical need. Over the course of a twenty-year career in industry, James has worked principally with Biogen (NASDAQ: BIIB), Takeda (NYSE: TAK), and Sanofi (NASDAQ: SNY), in regional and global roles. He has overseen more than thirty national product approvals, more than a dozen multinational clinical trials, several partnering transactions, and numerous scientific collaborations. His experience spans multiple therapeutic areas, including oncology, immunology, CNS, and orphan diseases. In his seven-year tenure as CEO and Managing Director of Kazia Therapeutics (NASDAQ: KZIA), James drove a transformation of the company’s pipeline by in-licensing clinical-stage assets from Genentech and Evotec, deployed an extensive pipeline of more than a dozen clinical trials across multiple oncology indications, and inked partnering deals with Simcere (HKSE:2096) and Vivesto AB (STO: VIVE). James has raised approximately US$ 40 million in equity financing for Kazia, and the company has also benefited significantly from non-dilutive opportunities.